Skip to main content
. Author manuscript; available in PMC: 2018 Sep 12.
Published in final edited form as: Cell Stem Cell. 2018 Feb 15;22(4):501–513.e7. doi: 10.1016/j.stem.2018.01.016

Figure 6. C+I vaccination leads to a systemic immune profile similar to positive control groups of tumor rejection and upregulation of vaccine-specific T-cell clones.

Figure 6

(A) Luminex analysis of serum from the different treatment groups at one week after tumor cell introduction reveals a significantly lower presence of systemic cytokines in the positive control mice (C+I/iPSC, C+A/AC29) compared to PBS control mice (PBS/AC29). The C+I/AC29 group follows a similar trend as the positive control samples (C+I/iPSC and C+A/AC29, ANOVA with Tukey’s multiple comparison test, *p<0.05, **p<0.001, ***p<0.001). (B) Among C+I vaccinated mice (C+I1 through C+I5/AC29), there was greater unique vaccine-associated variance within the TILs, whereas PBS-vaccinated mice (PBS1 through 5/AC29) demonstrated a higher uniformity among T-cells that are commonly present in lymphoid organs (Figure S6C-D).